tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Christopher Neyor, 9 are a BUY (81.82%), 1 are a SELL (9.09%), 1 are a HOLD (9.09%).
Analyst Christopher Neyor, currently employed at JPMORGAN, carries an average stock price target met ratio of 16.67% that have a potential upside of 9.1% achieved within 80 days.
Christopher Neyor’s has documented 20 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ITOS, Iteos Therapeutics at 13-May-2025.
Analyst best performing recommendations are on PCRX (PACIRA PHARMACEUTICALS).
The best stock recommendation documented was for PCRX (PACIRA PHARMACEUTICALS) at 7/26/2021. The price target of $75 was fulfilled within 239 days with a profit of $16.09 (27.31%) receiving and performance score of 1.14.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 21-Aug-2017
$30
$8.09 (36.92%)
$30
1 months 23 days ago
(09-Jan-2026)
4/22 (18.18%)
$6.47 (27.50%)
496
Buy Since 24-Feb-2020
$38
$16.09 (73.44%)
$38
1 months 23 days ago
(09-Jan-2026)
4/6 (66.67%)
$14.47 (61.50%)
889
Hold Since 12-Aug-2024
$26
$4.09 (18.67%)
$22
10 months 24 days ago
(08-Apr-2025)
3/13 (23.08%)
$-0.27 (-1.03%)
51
Buy Since 25-Feb-2022
$65
$43.09 (196.67%)
$70
10 months 24 days ago
(08-Apr-2025)
13/29 (44.83%)
$38.73 (147.43%)
233
Hold Since 12-Nov-2024
$17
$-4.91 (-22.41%)
$25
1 years 3 months 20 days ago
(12-Nov-2024)
4/12 (33.33%)
$0.2 (1.19%)
270
What Year was the first public recommendation made by Christopher Neyor?
